Lantheus Holdings Inc
NASDAQ:LNTH

Watchlist Manager
Lantheus Holdings Inc Logo
Lantheus Holdings Inc
NASDAQ:LNTH
Watchlist
Price: 96.92 USD 3.3% Market Closed
Market Cap: 6.7B USD
Have any thoughts about
Lantheus Holdings Inc?
Write Note

Lantheus Holdings Inc
Income from Continuing Operations

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Lantheus Holdings Inc
Income from Continuing Operations Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Income from Continuing Operations CAGR 3Y CAGR 5Y CAGR 10Y
Lantheus Holdings Inc
NASDAQ:LNTH
Income from Continuing Operations
$427.6m
CAGR 3-Years
N/A
CAGR 5-Years
65%
CAGR 10-Years
N/A
Haemonetics Corp
NYSE:HAE
Income from Continuing Operations
$123.8m
CAGR 3-Years
58%
CAGR 5-Years
13%
CAGR 10-Years
15%
DENTSPLY SIRONA Inc
NASDAQ:XRAY
Income from Continuing Operations
-$410m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
ICU Medical Inc
NASDAQ:ICUI
Income from Continuing Operations
-$111m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Align Technology Inc
NASDAQ:ALGN
Income from Continuing Operations
$441.6m
CAGR 3-Years
-16%
CAGR 5-Years
1%
CAGR 10-Years
12%
Merit Medical Systems Inc
NASDAQ:MMSI
Income from Continuing Operations
$120m
CAGR 3-Years
40%
CAGR 5-Years
40%
CAGR 10-Years
19%
No Stocks Found

Lantheus Holdings Inc
Glance View

Economic Moat
Wide
Market Cap
6.7B USD
Industry
Health Care

Lantheus Holdings Inc. is a captivating player in the healthcare sector, primarily operating within the niche of diagnostic medical imaging. The company's core mission revolves around enhancing diagnosis and treatment pathways, thus playing an integral role in patient care. At the heart of Lantheus's operations are its innovative diagnostic and therapeutic products, including radiopharmaceuticals and contrast agents that physicians rely on to obtain detailed images of the body's organs and tissues. Through a combination of proprietary technologies and strategic partnerships, Lantheus delivers solutions that help medical professionals make more informed clinical decisions, ultimately aiming to improve patient outcomes. This business generates revenue by developing, manufacturing, and commercializing its products, which are utilized across hospitals, clinics, and research centers worldwide. By consistently investing in research and development, Lantheus ensures a competitive edge through a robust pipeline of next-generation imaging agents. Strategic alliances and collaborative ventures further fortify its market presence, allowing the company to expand its reach and integrate new advancements into its product offerings. This commitment to innovation and collaboration has not only cemented its reputation in the life sciences industry but also ensures a steady and growing stream of income from its well-regarded product lines.

LNTH Intrinsic Value
128.34 USD
Undervaluation 24%
Intrinsic Value
Price

See Also

What is Lantheus Holdings Inc's Income from Continuing Operations?
Income from Continuing Operations
427.6m USD

Based on the financial report for Sep 30, 2024, Lantheus Holdings Inc's Income from Continuing Operations amounts to 427.6m USD.

What is Lantheus Holdings Inc's Income from Continuing Operations growth rate?
Income from Continuing Operations CAGR 5Y
65%

Over the last year, the Income from Continuing Operations growth was 311%.

Back to Top